Results

581 - 590 of 583 results for ‘See colaplug.com for buy mdma online’.

  • 19. Respiratory syncytial virus

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/19-respiratory-syncytial-virus

    Key information Mode of transmission Transmitted from respiratory secretions to nasopharyngeal or conjunctival mucosa, through close or direct contact with large droplets or fomites. Incubation period Ranges from two to eight days Period of communicability Average eight days, up to three weeks Available vaccines Unfunded – RSVpreF vaccine (Arexvy) – for active immunisation Unfunded – palivizumab – for passive immunoprophylaxis Dose, presentation, route RSV vaccine (Arexvy) 0.5 mL per dose Two glass vials – antigen powder must be reconstituted with adjuvant suspension. Intramuscular i ...

  • 3. Vaccination questions and addressing concerns

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/3-vaccination-questions-and-addressing-concerns

    ... vaccines (eg, rotavirus) and live parenteral vaccines (BCG), live and inactive vaccines, or two inactive vaccines. What steps are required if the Schedule is interrupted or varied? Generally, there is no need to repeat prior doses; simply continue the Schedule as if no interruption has occurred (see   Appendix 2 ). Special circumstances where the above does not apply are as follows: HepB given at birth to babies born to HBsAg-positive mothers – this dose does not count as part of a catch-up the two-dose course of rotavirus vaccine (RV1; Rotarix) should be started before age 15 we ...

  • 17. Pneumococcal disease

    http://corporat-prod.sites.silverstripe.com/for-health-professionals/clinical-guidance/immunisation-handbook/17-pneumococcal-disease

    Key information Mode of transmission Contact with respiratory droplets. Incubation period Asymptomatic nasopharyngeal carriage is common. The incubation period is variable and may be as short as 1–3 days. Incidence and burden of disease Highest at extremes of age (<2 years and >75 years), Māori and Pacific people, those with multiple comorbidities and with immunocompromise. Funded vaccines All children aged under 5 years: PCV13 (Prevenar 13). Children and adults with eligible conditions: PCV13 (Prevenar 13) 23PPV (Pneumovax 23). Dose, presentation and route All vaccines: 0.5 mL per do ...